Integra LifeSciences (NASDAQ:IART) Shares Gap Down After Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) gapped down before the market opened on Wednesday after Truist Financial lowered their price target on the stock from $13.00 to $12.00. The stock had previously closed at $11.06, but opened at $10.60. Truist Financial currently has a hold rating on the stock. Integra LifeSciences shares last traded at $11.01, with a volume of 97,263 shares trading hands.

Several other brokerages have also recently issued reports on IART. Wells Fargo & Company raised shares of Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday. Citigroup lowered their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Friday, March 27th. Finally, Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $14.20.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently added to or reduced their stakes in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Integra LifeSciences during the 1st quarter worth $277,000. Goldman Sachs Group Inc. boosted its position in Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after buying an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Integra LifeSciences by 23.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after buying an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Integra LifeSciences in the 2nd quarter valued at about $491,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Up 1.5%

The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. The business’s 50-day simple moving average is $10.23 and its two-hundred day simple moving average is $12.03. The company has a market capitalization of $874.80 million, a PE ratio of -1.66 and a beta of 1.06.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. The company had revenue of $434.93 million during the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.